A PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH AUTOLOGOUS MARROW SUPPORT IN WOMEN WITH MEASURABLE ADVANCED BREAST-CANCER RESPONDING TO STANDARD-DOSE THERAPY

被引：379

作者：

ANTMAN, K

AYASH, L

ELIAS, A

WHEELER, C

HUNT, M

EDER, JP

TEICHER, BA

CRITCHLOW, J

BIBBO, J

SCHNIPPER, LE

FREI, E

机构：

[1] HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT STAT, BOSTON, MA 02115 USA

[2] HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT CANC PHARMACOL, BOSTON, MA 02115 USA

[3] BETH ISRAEL HOSP, DEPT MED & SURG, BOSTON, MA 02215 USA

[4] HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA

来源：

关键词：

D O I：

10.1200/JCO.1992.10.1.102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：102 / 110

页数：9

共 72 条

[1] ANTMAN K, 1991, UCLA SYM BI, V137, P423
[2] ANTMAN K, 1987, CANCER TREAT REP, V71, P119
[3] BERETTA G, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P77
[4] BEVERIDGE RA, 1988, P ASCO, V7, P13
[5] BITRAN JD, 1987, BREAST CANCER RES TR, V10, P88
[6] BRUCE WR, 1966, JNCI-J NATL CANCER I, V37, P233
[7] THE DOSE DILEMMA
CANELLOS, GP
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) : 1363 - 1364
[8] SURVIVAL FROM 1ST RECURRENCE - RELATIVE IMPORTANCE OF PROGNOSTIC FACTORS IN 1,015 BREAST-CANCER PATIENTS
CLARK, GM
SLEDGE, GW
OSBORNE, CK
MCGUIRE, WL
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) : 55 - 61
[9] DUNPHY F, 1989, P AN M AM SOC CLIN, V8, P25
[10] DUNPHY FR, 1989, TANDEM HIGH DOSE CHE, P245